FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077928959> ?p ?o ?g. }

• W2077928959 abstract "Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DCAbnormal PI3K pathway activation plays a major role in cancer, as a result of either RTK activation or somatic mutations of major components of the pathway, including activating point mutations and amplification of the PIK3CA gene as well as loss of negative regulatory proteins such as PTEN. Most of the ATP-competitive PI3K inhibitors currently in clinical development inhibit all class I PI3K isoforms: however, several recent reports support the development of isoform-specific inhibitors. In particular, while PI3Kα specific inhibitors are predicted to inhibit growth of tumors with PIK3CA mutations, PTEN-deficient tumors have been shown to depend on PI3Kβ. In addition, isoform specific PI3K inhibitors may exhibit better safety profiles compared to pan-selective PI3K inhibitors, and thus may be easier to combine with other targeted or cytotoxic therapies. Here we report the discovery of ATP-competitive inhibitors with selectivity for PI3Kα, PI3Kα/mTOR, or PI3Kβ, which were identified and optimized by means of high-throughput screening and medicinal chemistry. These inhibitors exhibit biochemical IC50 values below 100 nM and good selectivity over other PI3K isoforms and a diverse panel of protein kinases. Cellular assays demonstrate that PI3Kα or PI3Kα/mTOR compounds inhibit phosphorylation of targets downstream of PI3K (Akt) and mTOR (S6 and p70S6 kinase) in the PI3Kα-activated MCF7 cell line, and that effects on PI3K pathway readouts are less pronounced in PC3 cells lacking PTEN. In contrast, PI3Kβ compounds potently inhibit phosphorylation of AKT (cellular IC50s < 200 nM) in the PTEN-deficient PC3 tumor cell line, and the most PI3Kβ-selective inhibitors are inactive on AKT phosphorylation in PI3Kα-activated H460 cells. In vivo pharmacodynamic analyses following oral administration of these isoform-selective inhibitors to mice bearing xenografted tumors demonstrate dose-dependent inhibition of phosphorylation of PI3K and mTOR effectors at well-tolerated doses.These results strongly argue for the development of isoform-selective PI3K inhibitors for the treatment of cancer patients harboring tumors with PTEN- deficient or PI3Kα-activated specific genotypes.Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend.Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4475." @default.
• W2077928959 created "2016-06-24" @default.
• W2077928959 creator A5001140173 @default.
• W2077928959 creator A5003144687 @default.
• W2077928959 creator A5010351175 @default.
• W2077928959 creator A5015626556 @default.
• W2077928959 creator A5020235332 @default.
• W2077928959 creator A5030049268 @default.
• W2077928959 creator A5032265961 @default.
• W2077928959 creator A5034583388 @default.
• W2077928959 creator A5037677450 @default.
• W2077928959 creator A5043472878 @default.
• W2077928959 creator A5045635957 @default.
• W2077928959 creator A5046614767 @default.
• W2077928959 creator A5047363846 @default.
• W2077928959 creator A5049495232 @default.
• W2077928959 creator A5050221240 @default.
• W2077928959 creator A5052089394 @default.
• W2077928959 creator A5052438850 @default.
• W2077928959 creator A5060009480 @default.
• W2077928959 creator A5066879227 @default.
• W2077928959 creator A5067248001 @default.
• W2077928959 creator A5070878700 @default.
• W2077928959 creator A5075768894 @default.
• W2077928959 creator A5079467950 @default.
• W2077928959 creator A5079494254 @default.
• W2077928959 creator A5080723502 @default.
• W2077928959 creator A5090815344 @default.
• W2077928959 creator A5091762910 @default.
• W2077928959 date "2010-04-15" @default.
• W2077928959 modified "2023-09-26" @default.
• W2077928959 title "Abstract 4475: Discovery and characterization of PI3K isoform-selective inhibitors" @default.
• W2077928959 doi "https://doi.org/10.1158/1538-7445.am10-4475" @default.
• W2077928959 hasPublicationYear "2010" @default.
• W2077928959 type Work @default.
• W2077928959 sameAs 2077928959 @default.
• W2077928959 citedByCount "0" @default.
• W2077928959 crossrefType "proceedings-article" @default.
• W2077928959 hasAuthorship W2077928959A5001140173 @default.
• W2077928959 hasAuthorship W2077928959A5003144687 @default.
• W2077928959 hasAuthorship W2077928959A5010351175 @default.
• W2077928959 hasAuthorship W2077928959A5015626556 @default.
• W2077928959 hasAuthorship W2077928959A5020235332 @default.
• W2077928959 hasAuthorship W2077928959A5030049268 @default.
• W2077928959 hasAuthorship W2077928959A5032265961 @default.
• W2077928959 hasAuthorship W2077928959A5034583388 @default.
• W2077928959 hasAuthorship W2077928959A5037677450 @default.
• W2077928959 hasAuthorship W2077928959A5043472878 @default.
• W2077928959 hasAuthorship W2077928959A5045635957 @default.
• W2077928959 hasAuthorship W2077928959A5046614767 @default.
• W2077928959 hasAuthorship W2077928959A5047363846 @default.
• W2077928959 hasAuthorship W2077928959A5049495232 @default.
• W2077928959 hasAuthorship W2077928959A5050221240 @default.
• W2077928959 hasAuthorship W2077928959A5052089394 @default.
• W2077928959 hasAuthorship W2077928959A5052438850 @default.
• W2077928959 hasAuthorship W2077928959A5060009480 @default.
• W2077928959 hasAuthorship W2077928959A5066879227 @default.
• W2077928959 hasAuthorship W2077928959A5067248001 @default.
• W2077928959 hasAuthorship W2077928959A5070878700 @default.
• W2077928959 hasAuthorship W2077928959A5075768894 @default.
• W2077928959 hasAuthorship W2077928959A5079467950 @default.
• W2077928959 hasAuthorship W2077928959A5079494254 @default.
• W2077928959 hasAuthorship W2077928959A5080723502 @default.
• W2077928959 hasAuthorship W2077928959A5090815344 @default.
• W2077928959 hasAuthorship W2077928959A5091762910 @default.
• W2077928959 hasConcept C104317684 @default.
• W2077928959 hasConcept C11960822 @default.
• W2077928959 hasConcept C184235292 @default.
• W2077928959 hasConcept C185592680 @default.
• W2077928959 hasConcept C2777609662 @default.
• W2077928959 hasConcept C502942594 @default.
• W2077928959 hasConcept C53345823 @default.
• W2077928959 hasConcept C55493867 @default.
• W2077928959 hasConcept C62478195 @default.
• W2077928959 hasConcept C75217442 @default.
• W2077928959 hasConcept C86554907 @default.
• W2077928959 hasConcept C86803240 @default.
• W2077928959 hasConcept C95444343 @default.
• W2077928959 hasConceptScore W2077928959C104317684 @default.
• W2077928959 hasConceptScore W2077928959C11960822 @default.
• W2077928959 hasConceptScore W2077928959C184235292 @default.
• W2077928959 hasConceptScore W2077928959C185592680 @default.
• W2077928959 hasConceptScore W2077928959C2777609662 @default.
• W2077928959 hasConceptScore W2077928959C502942594 @default.
• W2077928959 hasConceptScore W2077928959C53345823 @default.
• W2077928959 hasConceptScore W2077928959C55493867 @default.
• W2077928959 hasConceptScore W2077928959C62478195 @default.
• W2077928959 hasConceptScore W2077928959C75217442 @default.
• W2077928959 hasConceptScore W2077928959C86554907 @default.
• W2077928959 hasConceptScore W2077928959C86803240 @default.
• W2077928959 hasConceptScore W2077928959C95444343 @default.
• W2077928959 hasLocation W20779289591 @default.
• W2077928959 hasOpenAccess W2077928959 @default.
• W2077928959 hasPrimaryLocation W20779289591 @default.
• W2077928959 hasRelatedWork W1436721071 @default.
• W2077928959 hasRelatedWork W1638715632 @default.
• W2077928959 hasRelatedWork W1858739728 @default.
• W2077928959 hasRelatedWork W1973723861 @default.
• W2077928959 hasRelatedWork W1993215631 @default.
• W2077928959 hasRelatedWork W2014143780 @default.

• next